Evidence map›Paper›PMID 40773002›Full record

ArticleJapanese journal of ophthalmology2026

Comparison of 1-year outcomes after switching to faricimab in neovascular age-related macular degeneration previously treated with anti-VEGF agents with/without a loading phase.

Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Faricimab: current evidence for the treatment of retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Taiichi HikichiHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan. thikichi@hikichi-eye.jp.
Haruka KurabeHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Amane NotoyaHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Yuuna OguroHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Misaki HiranoHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.
Yumeka DoiHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-Building, 14 Floor, Kita-ku, Sapporo, 060-0807, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the 1-year outcomes after switching to faricimab with/without a loading phase of three monthly injections followed by a treat-and-extend (TAE) regimen in eyes with neovascular age-related macular degeneration previously treated with anti-VEGF agents. STUDY

designRetrospective consecutive case study.

methodsEyes with persistent exudative changes despite injection intervals of 10 weeks or less were switched to faricimab between June 2022 and December 2023 and included in this study. All eyes switched to faricimab between June 2022 and June 2023 received a single injection followed by a treat and extend (TAE) regimen (group 1). Thereafter, all eyes switched to faricimab received three consecutive monthly injections followed by a TAE regimen (group 2).

resultsOf 153 eyes switched to faricimab, 21 eyes (17 in group 1, four in group 2) were excluded because of discontinuation of faricimab due to persistent exudative changes despite bimonthly injections; 132 eyes of 132 patients were analyzed. Faricimab treatment significantly improved the best-corrected visual acuity, anatomic parameters, with extended injection interval 1 year after the switch in 132 eyes and 45 eyes of group 2. That improvement, except the injection interval in 87 eyes of group 1, did not reach significance. The injection interval in group 2 was extended significantly compared with group 1 (P=0.023).

conclusionSwitching to faricimab with a loading phase followed by a TAE regimen may improve outcomes in previously treated eyes. Further studies are warranted to confirm these findings.

Indexed as

Drug SubstitutionVisual AcuityWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMacula LuteaMaleRanibizumabAngiogenesis InhibitorsAntibodies, BispecificfaricimabRanibizumabVascular Endothelial Growth Factor AFaricimabLoading phaseNeovascular age-related macular degenerationSwitchingTreat-and-extend

Identifiers

PMID40773002

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.